Clinically meaningful visual improvements and predictors of early vision gains with ranibizumab for diabetic macular oedema

OBJECTIVE: To determine the time to first clinically meaningful improvement in best-corrected visual acuity (BCVA) in patients treated with ranibizumab for diabetic macular oedema (DME) and identify predictors of early visual improvement. METHODS AND ANALYSIS: We retrospectively analysed the phase I...

Descripción completa

Detalles Bibliográficos
Autores principales: Morse, Lawrence, Yau, Linda, Tuomi, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830470/
https://www.ncbi.nlm.nih.gov/pubmed/31750396
http://dx.doi.org/10.1136/bmjophth-2019-000335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830470/
https://www.ncbi.nlm.nih.gov/pubmed/31750396
http://dx.doi.org/10.1136/bmjophth-2019-000335

Ejemplares similares